In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on schedule Helene knocks out Baxter facility, creating shortage of IV fluids

Teclistamab extends OS, deepens remissions in landmark trial published in NEJM and presented at ASCO

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab (TECVALI) lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase III clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology annual meeting.

May 29, 2026

Vol.52 No.21

Collaborative work behind the scenes makes cancer breakthroughs possible

When we talk about breakthroughs in cancer research, most focus on the moment of discovery: a new therapy, a promising trial result, or a headline-grabbing study.

May 08, 2026

Vol.52 No.18

By Annaliese Daniels

In Brief

Neal Meropol named PI of ASCO’s TAPUR study

Neal J. Meropol was named principal investigator of the American Society of Clinical Oncology’s Targeted Agent and Profiling Utilization Registry study.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Microplastics are discovered in prostate tumors, NYU researchers present at ASCO GU

Small fragments of plastic were found in nine out of 10 patients with prostate cancer, and in higher levels inside tumors than in nearby noncancerous tissue, according to a study led by NYU Langone Health, its Perlmutter Cancer Center, and its Center for the Investigation of Environmental Hazards.

February 27, 2026

Vol.52 No.08

In Brief

UNC Health to offer advanced proton therapy

UNC Health is incorporating proton therapy into its established radiation oncology program at UNC Hospitals in Chapel Hill.

February 20, 2026

Vol.52 No.07

Clinical Roundup

Researchers create blueprint for designing CD8 killer T cells to kill cancer cells

Researchers have uncovered new genetic rules that determine how CD8 killer T cells choose between becoming long-lasting, protective defenders or slipping into exhausted, dysfunctional states.

February 06, 2026

Vol.52 No.05

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on schedule

Helene knocks out Baxter facility, creating shortage of IV fluids

YOU MAY BE INTERESTED IN

Teclistamab extends OS, deepens remissions in landmark trial published in NEJM and presented at ASCO

Collaborative work behind the scenes makes cancer breakthroughs possible

Neal Meropol named PI of ASCO’s TAPUR study

Microplastics are discovered in prostate tumors, NYU researchers present at ASCO GU

UNC Health to offer advanced proton therapy

Researchers create blueprint for designing CD8 killer T cells to kill cancer cells

Renew today!

Subscriber content

Never miss an issue!

Login